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Prescribing policy recommendations aimed at moving immunosuppressant prescribing for 4 
renal transplant patients from primary to secondary care may result in benefits of increased 5 
safety and reduced cost.  However, there is little evidence of patients’ preferences for 6 
receiving their immunosuppressant therapy from hospitals compared to community 7 
dispensing. The aim of this study was to elicit patient preferences for different service 8 
configurations focusing in particular on home delivery versus collection of medication from 9 
hospital.  10 
 11 
Methods 12 
A discrete choice experiment was administered to 265 renal transplant patients in North 13 
Wales. Respondents were presented 18 pairwise choices, labelled as either home delivery or 14 
hospital collection, and described by the attributes: frequency of supply, waiting time (for 15 
delivery or collection) and method of ordering (provider contact, patient contact via phone, 16 
patient contact electronically). Data were analysed using a random-effects logit model and 17 
marginal rates of substitution calculated based on the waiting time attribute. 18 
 19 
Results  20 
A response rate of 63% was achieved, with 5332 usable observations from 150 respondents. 21 
Method of delivery (β coefficient 1.21; 95% confidence interval 1.05 to 1.38), frequency of 22 
supply (0.05; 0.03 to 0.08) waiting time (-0.00, -0.00 to -0.00), provider contact (desirable) 23 
(0.20; 0.12 to 0.27), patient contact by telephone (desirable) (0.09; 0.01 to 0.17)  and patient 24 




(p<0.05). Results indicate that patients are willing to increase waiting time by nearly 10 1 
hours to have a home delivery service.  2 
 3 
Conclusion 4 
Patients indicate a clear preference for a home delivery service. They prefer providers to 5 
make contact when new immunosuppressant supplies are required and show preference 6 
against ordering medication electronically. A policy for secondary care prescribing and 7 
hospital collection of medicines does not align with this preference.  8 
 9 
Key words: 10 
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The safe and effective use of immunosuppressants in the prevention of organ transplant 3 
rejection requires careful prescribing, and a high degree of adherence. Adverse events may 4 
arise from missed doses [1], medication errors [2], from switching between different brands 5 
of the same immunosuppressants [3], or during dispensing. Measures to reduce the 6 
likelihood of adverse outcomes, including appropriate prescribing, medicines optimisation 7 
strategies and supporting medication adherence, are reinforced in clinical guidelines [4,5].  8 
Prescribing policies that promote the safer use of immunosuppressants in the UK have 9 
centred on increased specialist input from secondary care or tertiary centres to meet the 10 
pharmaceutical care needs of patients [6,7].  Patients may either collect a supply of their 11 
medication from the hospital pharmacy following a clinic appointment, or receive a delivery 12 
of their immunosuppressants by a registered pharmacy that specialises in home delivery. 13 
Patient preferences are important in the context of recommendations that patients should 14 
be given a choice in how their medicines are supplied [8]. However, we are aware of only 15 
one evaluation of patients’ perspectives of a home delivery service of immunosuppressants 16 
[9]. Conducted as a postal questionnaire involving 300 patients at the Oxford Transplant 17 
Centre, the study indicated over 98% respondents prefer the home delivery service to the 18 
medication supply service previously provided by the hospital.  However, the study was 19 
limited in terms of methodology through the use of a non-validated questionnaire, 20 
incomplete reporting and a risk of social desirability bias that might arise from patients’ 21 
reluctance to criticise their health care provider [10]. 22 
Discrete choice experiment (DCE) is a quantitative technique for eliciting patients’ stated 23 
preferences. It has been applied extensively to assess service users’ preferences for health 24 




allocation decisions.  Within a DCE, respondents are asked to choose between a set of 1 
hypothetical but realistic scenarios, which are each described by a number of characteristics 2 
(attributes) for which the levels are varied. DCEs assume that respondents’ preference is 3 
revealed through their choice decisions [12]. To our knowledge, the only DCEs conducted in 4 
renal transplant patients have considered prioritisation of transplant, rather than 5 
considering aspects of service delivery [13,14].  In the context of a policy change, moving 6 
prescribing from primary care (where patients obtain their medicines from a community 7 
pharmacy) to secondary care involving hospital pharmacies, we aim to elicit patients’ 8 
preferences for obtaining their immunosuppressive therapy via home-delivery or by 9 
collection from hospital pharmacies.  10 
 11 
Subjects and Methods 12 
Setting 13 
The health board in North Wales is responsible for three major hospitals, located in the 14 
West, Central and East of the region. The East region is mostly urban or semi-urban, whereas 15 
the West and Central areas are more rural with distances from patients’ homes to the 16 
nearest hospital being up to 60 miles and requiring up to 2 hours of travel time. Current 17 
supply of immunosuppressants is via collection alongside other medication prescribed by 18 
the general practitioner (GP) on a monthly basis from a local community pharmacy. However 19 
the policy recommendation is a change of prescribing responsibility from the GP to hospital 20 
(secondary care) based nephrologists.  This means that the supply of immunosuppressants 21 
has to be arranged by the hospital pharmacies, which can be direct collection from the 22 
hospital or provision of home deliveries.  23 





A mixed methods approach was taken, which involved qualitative research methods (focus 1 
groups) to inform the design of the DCE. Ethics approval was granted by the North Wales 2 
Research Ethics Committee (West) reference 11/WA/0244. 3 
DCE Attribute and level selection 4 
Initial attributes and levels of the prescribing service were based on clinical experience with 5 
home delivery services of erythropoiesis stimulating agents, a programme which initiated in 6 
North Wales in 2007, and a patient satisfaction questionnaire administered to 198 patients 7 
in 2008 (response rate 76.8%). Responses to the questionnaire highlighted the importance 8 
to patients of the location of medication delivery (home versus hospital versus GP) and 9 
identified a prolonged waiting time as a cause of patient dissatisfaction [15]. In the context 10 
of this work, waiting time refers to either the length of an allocated delivery time slot for a 11 
home delivery, or the time waiting in the hospital pharmacy for collection of the 12 
prescription. The time waiting in hospital may be substantially shorter and the collection of 13 
medicines from hospital pharmacy usually follows a clinic appointment, however time spent 14 
at home may be used more productively. The additional attribute of the interval of ordering 15 
was chosen to reflect clinical practice. 16 
Focus groups were convened to discuss the attributes and refine how they were to be 17 
presented as part of the DCE, to identify relevant levels, to ensure that they were important 18 
and relevant to the patient population and understood by DCE respondents [16]. Twenty 19 
patients, randomly sampled from the patient list of 265 patients, were sent an invitation 20 
letter outlining the key aims of the study and a consent form should they wish to participate 21 
in the focus groups. Nine patients consented to take part in the focus groups and two 22 
sessions were facilitated to maximise attendance considering participants’ work 23 




The purpose of the first focus group was to assess the relevance and importance of the 1 
identified attributes (waiting time, location of collection, interval between supplies, safety or 2 
risk of errors, and cost to the National Health Service (NHS) in the UK), and to identify any 3 
further attributes using a thematic analysis.  The second focus group considered the 4 
attribute list and again considered the relevance and importance, with a focus on 5 
phraseology, and potential attribute levels.  6 
Focus group participants did not identify any further attributes; however there was concern 7 
that the inclusion of a price proxy would result in different interpretation of the meaning of 8 
cost (e.g. cost to the patient, drug cost, overall service cost) in the context of healthcare 9 
being free at the point of delivery. It was decided, therefore, not to include a price proxy in 10 
the DCE. Waiting time was considered as an attribute to estimate DCE respondents’ 11 
willingness to give up time for improvements on other attributes. Clinical experience with 12 
home delivery of medicines and data on local hospital dispensary waiting times were 13 
considered when assigning levels to this attribute. Although the attribute pertaining to 14 
prescribing safety/ risk of errors was considered to be important to some focus group 15 
participants, it  was identified as not suitable for inclusion in the DCE as no meaningful levels 16 
could be established as no comparative risk data were available for the different service 17 
models. The final selection of attributes and levels used in the DCE are detailed in table 1. 18 
Table 1: Attributes and levels for the discrete choice experiment 19 
Attribute Definition Levels 
Supply 
Method 




Wait Waiting time on day of tablet 
collection / delivery 
Hospital supply: 





60, 150, 240 minutes 
Frequency  How often are tablets supplied? Every month 
Every 3 months 
Every 6 months 
Ordering  How do I order a new supply of 
my tablets? 
You don’t need to do anything – the 
provider contacts you when your tablets 
are ready for collection 
 
You order your tablets by phoning the 
provider 
 
You order your tablets from the 
provider by email or online 
 1 
DCE design 2 
A labelled design was used to keep choice sets realistic [17], and to allow for different levels 3 
to be assigned to the “waiting time” attribute for the two supply methods.  4 
A full factorial design would result in 54 (33x 21) profiles and 1,431 choice sets, hence a 5 
fractional factorial design was used to arrive at a manageable number of choices. The design 6 
was based on an orthogonal main effects design taken from a published design catalogue 7 
(Design 19a) [18]. Choice options were generated as LMA, a labelled experimental design, 8 
which allows for the independent estimation of alternative specific attribute effects aiming 9 
to increase participants’ familiarity with the context and reduce cognitive burden. The first 10 
three columns of the design correspond to attribute levels for choice A, and columns 4-6 of 11 




wise, with respondents being required to make a choice; no “opt out” alternative was 1 
presented, as the current situation of GP prescribing will not be continued and non-2 
participation, i.e. not receiving a supply of medication was not considered a valid choice. 3 
Figure 1 shows an example of one of the 18 choice sets in the DCE questionnaire. A 4 
dominant choice set, sometimes used to test for validity of responses, was not included as 5 
respondents’ preferred levels for each attribute were unknown a priori. 6 
 7 
*insert Figure 1 here* 8 
 9 
Information on respondents’ characteristics were collected to test the hypotheses that: (i) 10 
previous experience with home deliveries might result in preconceptions about the new 11 
service; (ii) travelling distance to the hospital clinic may influence a patient’s willingness to 12 
collect their medication from hospital; (iii) patients in full time employment may find home 13 
deliveries more inconvenient; (iv) access to a computer may facilitate medication ordering 14 
by email or online; and (v) patients may have different preferences depending on their 15 
region of residence, which determines the serving nephrology centre. Responses to other 16 
supplementary questions informed an assessment of the feasibility of providing a secondary 17 
care based prescribing service (e.g. establishing the risk of waste as a result of frequent 18 
changes to drug treatment or dosing). 19 
Considerate of the local population, the questionnaire was presented in a bilingual format 20 
(English and Welsh). 21 
 22 
Pilot 23 
Patients who attended either focus group meeting were invited to return for a second 24 




comment on various versions on the DCE questionnaire and the participant invitation letter, 1 
aiming to ensure that the DCE task was clearly presented and not overly burdensome. To 2 
facilitate understanding and consistency in respondents’ choices, a clearly explained 3 
example of a choice set was presented on the first page of the questionnaire. 4 
 5 
Recruitment 6 
Questionnaires were mailed to all transplant patients under the care of the three 7 
nephrology centres of the Betsi Cadwaladr University Health Board which serves the North 8 
Wales population of 678,000 people.  A pre-paid return envelope was included. Where 9 
necessary, one reminder was sent out two weeks after the initial distribution of the 10 
questionnaires.  Consent to participate was assumed with the return of completed 11 
questionnaires. 12 
Data analysis 13 
The DCE was analysed using a random effects logit model in STATA® Version 13 (Statacorp, 14 
TX), with choice of delivery method specified as the dependent variable. The home-delivery 15 
or hospital collection label was entered as the alternate specific constant. Effects coding was 16 
applied for categorical variables to ensure that preference statements could be interpreted 17 
independent of the current state [20]. The significance, sign and relative magnitude of the 18 
regression coefficients were used to estimate the importance of attributes. A positive 19 
coefficient indicates that higher levels of the attribute are preferred. Trade-offs among 20 
attributes were estimated by marginal rates of substitution (MRS), calculated as the ratio of 21 
coefficients of one attribute relative to the coefficient for waiting time. From this, the 22 
amount of extra time which a patient is willing to wait for different levels of other attributes 23 




Utilities of home delivery and hospital supply were calculated by weighting the results of the 1 
regression against potential outcomes using the formula  2 
Utility =  𝛽Delivery ∗ Delivery + 𝛽Freq ∗ Frequency + 𝛽Wait ∗ Wait + 𝛽Provider ∗ Provider3 
+ 𝛽Phone ∗ Phone +  𝛽Electronic ∗ Electronic 4 
 5 
We assumed home deliveries would be made on a 3-monthly basis with a typical wait of 4 6 
hours; whilst for hospital supply, we assumed a 20 minute waiting time, 3-monthly delivery, 7 
and telephone contact for re-supply. 8 
 9 
Confidence intervals for coefficients and MRS were calculated using a non-parametric 10 
bootstrap approach. Subgroup analyses were performed to aid further interpretation and 11 
generalisability of the results. These were defined a priori according to patients’ experience 12 
of home delivery; region; distance to clinic; employment status and type of transport.  A 13 
subgroup was considered valid for analysis if it included 50 or more patients; we considered 14 
smaller samples to lack statistical powering. Subgroup models were compared with the 15 
base-case model for goodness of fit using a log-likelihood ratio test. The potential for false 16 
positive results from multiple comparisons required a Bonferroni correction which reduced 17 
the p-value for 95% significance to p=0.0125. 18 
 19 
Results 20 
All 265 renal transplant patients across North Wales were invited to participate. Of these, 21 
166 questionnaires were returned, resulting in an overall response rate of 63%.  The 22 
response rate varied by region of nephrology centre: 55.8% for east, 62.5% for central and 23 
72.3% for west. Patient characteristics are summarised in Table 2. 24 





Age [years], n (%), N=166  
 18 to 30 3 (1.8) 
 31 to 50 48 (28.9) 
 51 to 70 83 (50.0) 
 Over 70 32 (19.3) 
Gender, n (%), N=166 
 Male 108 (65.1) 
   
Betsi Cadwaladr University Health Board Region, n (%), N=164 
 East 72 (43.9) 
 Central 45 (27.4) 
 West 47 (28.7) 
Current supply of immunosuppressants, n (%), N=162 
 GP and community pharmacy 125 (77.2) 
 GP (dispensing practice) 19 (11.7) 
 Hospital  18 (11.1) 
Transport to clinic, n (%), N=151  
 Car 128 (84.8) 
 Public transport 15 (9.9) 
 Taxi 0 (0) 
 Hospital transport 8 (5.3) 
 Walk 0 (0) 
 Other 0 (0) 




 <20 111 (71.2) 
 ≥20 45 (28.8) 
Travelling time local transplant clinic [min], mean (SD), N=147 34 ( 32.0) 
 <30 84 (57.1) 
 ≥30 63 (42.9) 
Experience with home delivery, n (%), N=162 
 Yes 69 (42.6) 
 No 93 (57.4) 
Employment status, n (%), N=159 
 Full time work 42 (26.4) 
 Part time work 20 (12.6) 
 Not in employment/ retired 97 (61.0) 
Access to the internet at home, n (%), N=159  
 Yes 115 (72.3) 
 No 44 (27.7) 
Last change to immunosuppressant medication, n(%), N=163  
 In previous 1 month 17 (10.4) 
 In previous 1-3 months 14 (8.6) 
 In previous 3-6 months 16 (9.8) 
 More than 6 months  116 (71.2) 
The number of patients (N) varies due to missing data 1 
Seven DCE responses were excluded as respondents’ annotations of the questionnaire 2 
clearly indicated a limited understanding of the DCE methodology. Nine further responses 3 
were excluded due to a small number (6 or less) of completed choice sets.  133 respondents 4 




preference towards either home deliveries (n = 55) or hospital supply (n=21), that is, they 1 
were non-traders. These were included in the base case analysis, resulting in 5,332 2 
observations from 150 patients.  3 
Base case results 4 
All attributes were statistically significant (p<0.05). The directions of coefficients are 5 
consistent with expectations, where hypothesised a priori. For example the negative 6 
coefficient (βWait = -0.0021) for waiting time indicates a preference towards a shorter wait for 7 
medication supply. Table 3 summarises the results of the base case model. 8 
Table 3: Discrete choice modelling results 9 
Attribute β-coefficient 
(95% confidence interval) 
P-value Marginal rate of substitution 
(95% confidence interval) 
Home deliveries 1.21 (1.05, 1.38) 0.000 588 (422, 1010) 
Frequency 0.05 (0.03, 0.08) 0.000 26 (12, 54) 
Wait -0.00 (-0.00, -0.00) 0.000 n/a 
Ordering_provider  0.20 (0.12, 0.27)  96 (50, 196) 
_ phone 0.09 (0.01, 0.17) 0.026 43 (5, 110) 
_ electronic -0.29 (-0.37, -0.21) 0.000 -139 (-276, -85) 
Constant -0.61 (-0.75, 0.50) 0.000 n/a 
 10 
The absolute values of coefficients indicate their relative importance on patients’ choice. 11 
Method of delivery had the greatest absolute value of the coefficient (βDelivery = 1.21, 95% CI 12 
1.05 to 1.39), followed by the methods patient order their medication supply. The frequency 13 
of supply (βFreq = 0.05, 95% CI 0.03 to 0.08) and a unit change in waiting time [minutes] (βWait 14 
= -0.00, 95% CI -0.00 to -0.00) were the least important attributes. Patients were more likely 15 




health care provider. Increased waiting time and the need for patients to initiate the 1 
medication ordering process themselves –either by phone or online– decreased the 2 
probability of patients choosing a method of medication delivery. 3 
Based on calculations of marginal rates of substitution (MRS), the results indicate that 4 
patients will accept an additional 26 minutes (95% CI, 12 to 54 minutes) of waiting time if 5 
the interval between medication supplies was increased by one month. Home delivery 6 
supplies were valued at almost 10 hours of waiting time. A reduction in waiting time of over 7 
2 hours would be required for patients to accept online ordering of their medications.  8 
Total utility for home delivery was 0.458 (95% CI 0.316 to 0.601). Hospital supply yielded a 9 
significantly lower utility of -0.410 (95% CI -0.514 to -0.302). 10 
Subgroup analysis 11 
Four subgroups satisfied the criteria for analysis: region (west and central versus east), 12 
distance to clinic, experience with home deliveries, and employment status. All subgroups 13 
were shown to be significant in terms of model fit, compared with the base case (p<0.01). 14 
Patients served by the central and west (more rural) regional nephrology centres within the 15 
Health Board show a higher preference to home deliveries than patients in the east, with a 16 
willingness to wait an extra 711 minutes (more than 11¾ hours) and 444 minutes (almost 7½ 17 
hours) for home delivery, respectively. The travel attribute was not significant for patients 18 
living within 30 minutes of their local hospital clinic; but for those living 30 minutes or more 19 
away, were willing to wait an extra 347 minutes (5¾ hours) for home delivery.  20 
Patients with previous experience of home deliveries show a weaker preference for home 21 
delivery supply compared to those who have not received medication deliveries to their 22 




compared to 623 minutes (over 10 hours), respectively. Of all subgroups, patients in full time 1 
employment showed the lowest preference for home deliveries and willing to increase 2 
waiting time by only 271 minutes (4½ hours) for this service.  3 
Marginal rates of substitution (Online appendix A1) for the subgroup analysis showed no 4 
significant differences in trading, either among subgroups, or compared to the base case. 5 
Discussion 6 
The present study reports on preferences of renal transplant patients in North Wales for the 7 
method of obtaining supplies of immunosuppressive therapy. We found the method of 8 
delivery to have, by far, the greatest impact on patients’ preference, with home deliveries 9 
identified as the preferred option. Respondents were willing to increase wait time by nearly 10 
10 hours for home delivery, and patients’ utility, based on a typical home delivery service, 11 
was significantly higher than for collection at hospital pharmacies. The least desired 12 
attribute was electronic ordering, with respondents willing to increase waiting time by over 13 
2 hours extra to avoid this option. This result should be in the context of 28% of respondents 14 
not having access to the internet at home. 15 
 16 
Patients were more likely to choose a delivery method if the interval between deliveries was 17 
high and the initial contact for ordering a supply was made by the health care provider. 18 
Implementing a service addressing both these attributes may however significantly increase 19 
the cost of providing the service: more staffing time is required for actively contacting 20 
patients compared to responding to requests for a medication supply. Increased intervals 21 
between deliveries may result in medication wastage due to dose changes or expired 22 
medication if stocks are not rotated following the receipt of a new supply. However, in the 23 
sampled population, the risk of medication wastage due to dose changes is low as most 24 





Analysis of marginal rates of substitutions within the subgroups “region” and “distance to 2 
hospital” supports the hypothesis that patients living further away from the base hospital in 3 
rural settings have a stronger preference for home deliveries compared to patients in an 4 
urban setting.  No published studies have been identified that explored the influence of 5 
rurality on patient’s preference on the method of medication supply in transplant patients 6 
or other patient groups.  Our findings add to other known characteristics of transplant 7 
patients who do not live in close proximity to a hospital. Research from the USA, for 8 
instance, indicates that distance to a transplant centre may reduce transplant waiting list 9 
registration rate and transplant rate [21,22] while patients living in rural areas may exhibit 10 
reduced adherence to immunosuppressant therapy [23] compared to patient in urban areas. 11 
No similar studies on the possible impact of rurality on renal transplant patients have been 12 
published in the UK [24]. 13 
 14 
The results of this study are generalizable to other regions of Wales and to other 15 
comparable regions of the UK. Despite the administration of the NHS having been devolved 16 
to individual countries within the UK, the delivery of pharmacy services for transplant 17 
patients is modelled on the same options as considered in our DCE. While North Wales is 18 
sparsely populated in comparison to many urban locations in the UK, our sub-group analysis 19 
allowed for exploration of differences between urban and rural regions, and indicated a 20 
higher preference for pharmacy collection in populated areas which are closer to hospitals. 21 
Many countries operate a home delivery service, and our analysis of patients with prior 22 
experience of this indicates that they would prefer not to wait as long for their medicines 23 
compared to patients with no prior experience. This may indicate a revealed preference of 24 
some dissatisfaction with home delivery service, though overall, this was still greatly 25 




restricted in its generalisability to healthcare systems and settings where the choice of 1 
attributes and their associated levels are applicable, and which are represented by our 2 
sample population. As such, the findings may have limited generalisability to patients, 3 
payers, healthcare systems or jurisdictions beyond the UK. 4 
 5 
The study benefited from an acceptable response rate and a high proportion of 6 
questionnaires completed in full. We used a rigorous and robust choice-based format to 7 
elicit patients’ stated preferences, and a systematic approach to identify relevant attributes 8 
and assign appropriate levels. 9 
 10 
There are a few caveats to the study, however, including responder bias arising from the 11 
familiarity of patients in the west region with the lead researcher, and opt-out being offered 12 
while patients were in possession of the questionnaires (those who did not participate might 13 
not have done so because they had first read through the questionnaire). A second potential 14 
limitation was the use of a forced choice format which, while being appropriate to the policy 15 
context, does not allow for patients to indicate that they did not prefer one supply method 16 
over the other. Inclusion of an option of “no preference”, however, would have impacted on 17 
the number of discrete choices to the extent that response rate might have been adversely 18 
affected. Labelling the choice sets with the two possible supply methods represented a third 19 
limitation as this led to a significant number of patients exhibiting a dominant preference by 20 
choosing home deliveries irrespective of the levels of other attributes in the choice set. We 21 
also note that when analysing data on waiting time, no distinction was made between time 22 
waiting at the hospital versus time waiting at home, and no account was made for travel 23 
time to the hospital, however given that patients collect their prescriptions following an 24 
appointment, this is not an additional expense. No attributes describing adherence to 25 




frequency of clinic appointments with either method of medication delivery, collection of 1 
medicines at hospital pharmacies might provide an opportunity for patient counselling, 2 
including matters relating to adherence. Finally, a transcription error meant that 2 of the 18 3 
choice sets did not correspond to the original design; but extensive testing for level balance 4 
and orthogonality confirmed that neither were compromised nor affected the validity of the 5 
results.  6 
 7 
Waiting times are often used as a key performance indicator to measure workload and 8 
performance in pharmacy outpatient medication supplies. However, this study showed that 9 
patients are willing to accept a significant increase in waiting time for other preferred 10 
attributes describing a medication supply service. This should be considered by policy 11 
decision makers when evaluating services affecting medication supply. Recent changes to 12 
commissioning of solid organ transplantation by NHS England (2014) will result in a 13 
significant shift of immunosuppressant prescribing from primary care to transplant centres 14 
or secondary care providers with assumed benefits on prescribing safety and cost [7]. The 15 
implication of a strong preference for home delivery service, particularly for patients more 16 
distant from specialist renal centres, ought to be considered in future commissioning of 17 
pharmaceutical services.  18 
 19 
Conclusions 20 
These first insights into the preferences of renal transplant patients suggest that patients 21 
have a preference for home-delivery of their immunosuppressant medications. The strength 22 
of this preference is increased for patients who live in more rural areas, but decreases in 23 
patients who are in full time employment. These findings and influencing factors should be 24 






Ethics: Ethics approval was granted by the North Wales Research Ethics Committee (West) 2 
reference 11/WA/0244. 3 
Consent for publication: Not applicable 4 
Availability of data and material: The datasets generated and/or analysed during the current 5 
study are not publicly available due to containing patient-level data. Data are available from 6 
the corresponding author, who will consider the purpose of the request and consider 7 
research duplication and resource implications for its provision. 8 
Competing interests: The authors declare no competing interests 9 
Funding: This research was supported, in part, by funding from the Welsh Assembly 10 
Government Pharmacy Practice Development Scheme 2010/11. DH is a Health and Care 11 
Research Wales Senior Research Leader. 12 
Authors' contributions: The authors certify to have made substantial contributions to the 13 
conception or design of the work (AH, DH); the acquisition, analysis, or interpretation of data 14 
for the work (AH, CP, DH); drafting the work (AH, CP), revising it critically for important 15 
intellectual content (DH); final approval of the version to be published (AH, CP, DH); 16 
agreement to be accountable for all aspects of the work in ensuring that questions related 17 
to the accuracy or integrity of any part of the work are appropriately investigated and 18 
resolved (AH, CP, DH). 19 
Acknowledgements: The authors thank Dr Verity Watson of the Health Economics Research 20 
Unit, University of Aberdeen for helpful methodological advice. 21 







1. Pinsky BW, Takemoto SK, Lentine KL, Burroughs TE, Schnitzler MA, Salvalaggio PR. 3 
Transplant outcomes and economic costs associated with patient noncompliance to 4 
immunosuppression. Am J Transplant. 2009;9(11):2597-606. 5 
2. MHRA. Ciclosporin: must be prescribed and dispensed by brand name. Drug Safety 6 
Update, Volume 3, Issue 5. 2009. 7 
http://webarchive.nationalarchives.gov.uk/20091211222914/http://mhra.gov.uk/Public8 
ations/Safetyguidance/DrugSafetyUpdate/CON065444 Accessed 18 May 2016  9 
3. MHRA. Oral tacrolimus products: measures to reduce risk of medication errors. Drug 10 
Safety Update Volume 3, Issue 10. 2010. 11 
http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/12 
Safetyinformation/DrugSafetyUpdate/CON085144 Accessed 18 May 2016 13 
4. Baker R, Jardine A, Andrews P. Renal Association Clinical Practice guidelines on post-14 
operative care of the kidney transplant recipient. Nephron Clin Pract. 2011;118 Suppl 15 
1:c311-47. 16 
5. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA et al. KDIGO Clinical 17 
practice guidelines for the care of kidney transplant recipients. Am J Transplant. 2009 18 
Nov;9 Suppl 3:S1-155.  19 
6. Welsh Renal Clinical Network Board. Minutes of meeting held on 19 July 2012. 20 
http://www.wales.nhs.uk/sites3/Documents/773/WRCN%20Network%20Board%20Min21 
utes%20--%2019th%20July%202012.pdf Accessed 18 May 2016 22 
7. NHS Commissioning Board. A07/S/a - NHS standard contract for adult kidney transplant 23 
service schedule 2. 2013. http://www.england.nhs.uk/commissioning/wp-24 





8. ESPRIT Efficacy and Safety of Prescribing In Transplantation. Guidance on Management 1 
of Repatriation and Immunosuppressant Switches in Transplant Patients. 2015. 2 
http://www.esprit.org.uk/wp-content/uploads/2015/08/Switch-guidance-document-3 
final-Aug-31-2015.pdf Accessed 18 May 2016 4 
9. Prowse A, Scott D.  An evaluation of clinic-based pharmacist and a medicines home 5 
delivery service from a transplant outpatient department. Pharmaceutical Journal.2004; 6 
(272):547-51. 7 
10. Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM et al. Eliciting public 8 
preferences for healthcare: a systematic review of techniques. Health Technol Assess. 9 
2001;5(5):1-186. 10 
11. Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW.  Discrete choice 11 
experiments in health economics: a review of the literature. Pharmacoeconomics. 2014 12 
Sep;32(9):883-902. 13 
12. Ryan M, Gerard K, Amaya-Amaya M. Using Discrete Choice Experiments to Value Health 14 
and Health Care. Springer. Dordrecht. The Netherlands: 2008. 15 
13. Clark MD, Leech D, Gumber A, Moro D, Szczepura A, West N et al. Who should be 16 
prioritized for renal transplantation?: Analysis of key stakeholder preferences using 17 
discrete choice experiments. BMC Nephrol. 2012 Nov 22;13:152. 18 
14. Davison SN, Kromm SK, Currie GR. Patient and health professional preferences for organ 19 
allocation and procurement, end-of-life care and organization of care for patients with 20 
chronic kidney disease using a discrete choice experiment Nephrol Dial Transplant. 2010 21 
Jul;25(7):2334-41. 22 
15. Willms A, Hodson K. Evaluation of the effects of introducing a non medical anaemia 23 
management team and a darbepoetin alfa home delivery service for patients with 24 
anaemia of chronic kidney disease. Poster publication; UK Renal Pharmacy Group 25 




16. Coast J, Horrocks S. Developing attributes and levels for discrete choice experiments 1 
using qualitative methods. J Health Serv Res Policy. 2007 Jan;12(1):25-30. 2 
17. Kruijshaar ME, Essink-Bot ML, Donkers B, Looman CW, Siersema PD, Steyerberg EW. A 3 
labelled choice experiment adds realism to the choices presented: preferences for 4 
surveillance tests for Barrett esophagus. BMC Med Res Methodol. 2009 May 19;9:31. 5 
18. Hahn GH, Shapiro SS. A catalogue and computer program for the design and analysis of 6 
orthogonal symmetric and asymmetric fractional factorial experiments; Technical report 7 
no 66-C-165; Schenectady, NY: General Electric Research and Development Centre. 8 
1966. 9 
19. Louviere JJ, Hensher DA, Swait JD.  Stated choice methods: Analysis and application. 10 
Cambridge University Press, Cambridge, UK: 2000. 11 
20. Bech M, Gyrd-Hansen D. Effects coding in discrete choice experiments. Health Econ. 12 
2005 Oct;14(10):1079-83. 13 
21. Axelrod DA, Guidinger MK, Finlayson S, Schaubel DE, Goodman DC, Chobanian M et al. 14 
Rates of solid-organ wait-listing, transplantation, and survival among residents of rural 15 
and urban areas. JAMA. 2008 Jan 9;299(2):202-7. 16 
22. Tonelli M, Klarenbach S, Rose C, Wiebe N, Gill J. Access to kidney transplantation among 17 
remote- and rural-dwelling patients with kidney failure in the United States. JAMA. 2009 18 
Apr 22;301(16):1681-90. 19 
23. Sankaranarayanan J, Collier D, Furasek A, Reardon T, Smith LM, McCartan M et al. 20 
Rurality and other factors associated with adherence to immunosuppressant 21 
medications in community-dwelling solid-organ transplant recipients; Res Social Adm 22 
Pharm. 2012 May-Jun;8(3):228-39. 23 
24. Ravanan R, Udayarai U, Ansell D, Collett D, Johnson R, O’Neill J et al. Variation between 24 






Figure 1: Example of choice set 2 
Question  Which methods of obtaining your anti-rejection drugs would you prefer if 3 
these were the only options available to you: 4 
 5 
 Hospital supply Home deliveries 
How often are tablets 
supplied? 
Every month Every 6 months 
Waiting time on day of 
tablet collection/ delivery: 
20 minutes 2.5 hours 
How do I order a new 
supply of my tablets? 
You order your tablets by 
phoning the hospital 
You order your tablets by 
phoning the delivery 
company 
   
Which medication supply 
service would you prefer? 
(please tick one box only) 
Prefer hospital supply Prefer home deliveries 
☐ ☐ 
 6 
 7 
